EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

STUDY OF CD163 AND B2M AS MARKERS FOR HODGKIN LYMPHOMA IN HUMAN AND ITS RELATION WITH CLINICO–PATHOLOGICAL BEHAVIOR

Hossam Darwish*, Lamiaa Barakat and Rania Bondok

ABSTRACT

Background: Hodgkin lymphoma is the most non malignancies at young adult ages, and is a curable disease in most patients. In the present study, our suggestion is to use CD163 and B2M as supplementary markers for the prognosis concerning Hodgkin lymphoma. So, identification of sensitive biomarkers to improve the prognosis related Hodgkin lymphoma is needed. Aim of the work: The aim of present study was to discuss the prognosis utility of serum CD163 and serum B2M in patients for Hodgkin lymphoma during and post therapy the clinical advantage of these markers will be decreased or normal during or post therapy. CD163 will be compared with B2M which is a routinely marker used for diagnosis and in follow up the patients for Hodgkin lymphoma. Results: Serum CD163 was significantly in most patients for Hodgkin lymphoma. The receiver operating characteristic curve (ROC) showed the best cut off values for CD163 and B2M were 5.0 ng/ml and 2.50 mg/l respectively. Area under the curve of CD163 and B2M were significantly 0.79 and 0.78. The sensitivity of CD163 and B2M were 76.7% and 66.7% respectively. Conclusion: Results revealed that serum CD163 may be used as potential prognostic markers for Hodgkin lymphoma patients.

Keywords: Hodgkin lymphoma patients, Cluster of Differentiation 163 (CD163), Beta 2 microglobulin (B2M).

[Full Text Article] [Download Certificate]